Bicara Therapeutics Inc. (NASDAQ: BCAX) announced the successful closing of its public offering, generating approximately $172.5 million in gross proceeds. The offering comprised 8,581,250 common shares and 2,200,000 pre-funded warrants, with underwriters exercising their option to purchase additional shares in full, indicating strong investor demand for the clinical-stage biopharmaceutical company's equity.
The capital raise represents a significant funding milestone for the company as it accelerates development of ficerafusp alfa, its lead therapeutic candidate. The bifunctional antibody is being developed as a first-in-class treatment for solid tumors and represents a novel approach to immunotherapy. Bicara intends to allocate the proceeds across multiple strategic priorities, including advancement of regulatory filings, manufacturing scale-up, and preparation for potential commercial launch.
The completion of the oversubscribed offering reflects investor confidence in Bicara's pipeline and clinical strategy. The company plans to deploy the capital to strengthen its competitive position in the solid tumor immunotherapy market while maintaining operational flexibility for clinical development initiatives. The full exercise of the underwriters' option underscores robust institutional participation in the offering.